News

Eli Lilly has agreed to acquire in vivo CAR-T developer Orna Therapeutics in a deal worth up to $2.4 billion, marking another rapid move to strengthen its research pipeline. The transaction positions Lilly buys Orna for $2.4bn as a...

Roche announced late-breaking Phase III data showing that fenebrutinib reduces disability progression in PPMS, marking the first investigational advance for primary progressive multiple sclerosis in more than a decade. Results from the FENtrepid study showed the Bruton’s tyrosine kinase...

Innovent Biologics has announced a strategic Innovent-Lilly partnership with Eli Lilly and Company to advance the global development of new medicines in oncology and immunology. The agreement represents the seventh partnership between the two companies and introduces a new...

GSK’s new chief executive, Luke Miels, said the drugmaker will prioritise faster drug development as it enters its next phase of growth, with a tighter focus on programmes that can change standards of care and selective bolt-on acquisitions. Miels,...

The UK and Japanese governments have announced a wide-ranging partnership that sees UK and Japan strengthen science and technology ties across pharmaceuticals, genomics, quantum computing and advanced manufacturing. The agreement was confirmed during a visit to Japan by the...

ACG Packaging Materials has announced that its Shirwal manufacturing facility has been formally designated a global Lighthouse and admitted into the World Economic Forum’s (WEF) Global Lighthouse Network (GLN). With this recognition, ACG becomes the world’s first pharmaceutical packaging...

For people with type 2 diabetes, medication choices often balance glucose control with side effects, weight impact, and practical access. Combination therapies such as sitagliptin/metformin (brand: Janumet) sit within that balance. They are used to improve glycemic control and...